{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:30:17Z","timestamp":1770539417005,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008645","name":"Terumo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Radiation pneumonitis is a serious complication of radioembolization. In holmium-166 ([<jats:sup>166<\/jats:sup>Ho]) radioembolization, the lung mean dose (LMD) can be estimated (eLMD) using a scout dose with either technetium-99\u00a0m-macroaggregated albumin ([<jats:sup>99m<\/jats:sup>Tc]MAA) or [<jats:sup>166<\/jats:sup>Ho]-microspheres. The accuracy of eLMD based on [<jats:sup>99m<\/jats:sup>Tc]MAA (eLMD<jats:sub>MAA<\/jats:sub>) was compared to eLMD based on [<jats:sup>166<\/jats:sup>Ho]-scout dose (eLMD<jats:sub>Ho-scout<\/jats:sub>) in two prospective clinical studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and Methods<\/jats:title>\n                <jats:p>Patients were included if they received both scout doses ([<jats:sup>99m<\/jats:sup>Tc]MAA and [<jats:sup>166<\/jats:sup>Ho]-scout), had a posttreatment [<jats:sup>166<\/jats:sup>Ho]-SPECT\/CT (gold standard) and were scanned on the same hybrid SPECT\/CT system. The correlation between eLMD<jats:sub>MAA<\/jats:sub>\/eLMD<jats:sub>Ho-scout<\/jats:sub> and LMD<jats:sub>Ho-treatment<\/jats:sub> was assessed by Spearman\u2019s rank correlation coefficient (<jats:italic>r<\/jats:italic>). Wilcoxon signed rank test was used to analyze paired data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-seven patients with unresectable liver metastases were included. During follow-up, none developed symptoms of radiation pneumonitis. Median eLMD<jats:sub>MAA<\/jats:sub> (1.53\u00a0Gy, range 0.09\u201321.33\u00a0Gy) was significantly higher than median LMD<jats:sub>Ho-treatment<\/jats:sub> (0.00\u00a0Gy, range 0.00\u20131.20\u00a0Gy; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Median eLMD<jats:sub>Ho-scout<\/jats:sub> (median 0.00\u00a0Gy, range 0.00\u20131.21\u00a0Gy) was not significantly different compared to LMD<jats:sub>Ho-treatment<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). In all cases, eLMD<jats:sub>MAA<\/jats:sub> was higher than LMD<jats:sub>Ho-treatment<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). While a significant correlation was found between eLMD<jats:sub>Ho-scout<\/jats:sub> and LMD<jats:sub>Ho-treatment<\/jats:sub> (<jats:italic>r<\/jats:italic>\u2009=\u20090.43, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), there was no correlation between eLMD<jats:sub>MAA<\/jats:sub> and LMD<jats:sub>Ho-treatment<\/jats:sub> (<jats:italic>r<\/jats:italic>\u2009=\u20090.02, <jats:italic>p<\/jats:italic>\u2009=\u20090.90).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>166<\/jats:sup>Ho]-scout dose is superior in predicting LMD over [<jats:sup>99m<\/jats:sup>Tc]MAA, in [<jats:sup>166<\/jats:sup>Ho]-radioembolization. Consequently, [<jats:sup>166<\/jats:sup>Ho]-scout may limit unnecessary patient exclusions and avoid unnecessary therapeutic activity reductions in patients eligible for radioembolization.<\/jats:p>\n                <jats:p><jats:italic>Trail registration<\/jats:italic>: NCT01031784, registered December 2009. NCT01612325, registered June 2012.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00270-023-03656-y","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T20:02:12Z","timestamp":1707336132000},"page":"443-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [166Ho]-Scout Over [99mTc]MAA in a Prospective Cohort Study"],"prefix":"10.1007","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct01031784","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01612325","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3836-2604","authenticated-orcid":false,"given":"Martijn E. H. M.","family":"Wagemans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten L. J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutger C. G.","family":"Bruijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jip F.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guus M.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo W. A. M.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marnix G. E. H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"3656_CR1","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3656_CR2","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00259-014-2784-9","volume":"41","author":"M Elschot","year":"2014","unstructured":"Elschot M, Nijsen JFW, Lam MGEH, Smits MLJ, Prince JF, Viergever MA, et al. 99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41:1965\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3656_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.23736\/S1824-4785.20.03287-2","volume":"65","author":"CS Kappadath","year":"2021","unstructured":"Kappadath CS, Lopez BP, Salem R, Lam MG. Lung shunt and lung dose calculation methods for radioembolization treatment planning. Q J Nucl Med Mol Imaging. 2021;65:32\u201342.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"3656_CR4","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00270-018-1982-4","volume":"41","author":"MTM Reinders","year":"2018","unstructured":"Reinders MTM, Mees E, Powerski MJ, Bruijnen RCG, van den Bosch MAAJ, Lam MGEH, et al. Radioembolisation in Europe: a survey amongst CIRSE members. Cardiovasc Intervent Radiol. 2018;41:1579\u201389.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"3656_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2967\/jnumed.121.263143","volume":"63","author":"M Stella","year":"2022","unstructured":"Stella M, van Rooij R, Lam MGEH, de Jong HWAM, Braat AJAT. Lung dose measured on postradioembolization 90Y PET\/CT and incidence of radiation pneumonitis. J Nucl Med. 2022;63(7):1075\u201380.","journal-title":"J Nucl Med"},{"key":"3656_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00259-019-04460-y","volume":"47","author":"M Smits","year":"2020","unstructured":"Smits M, Dassen M, Prince J, Braat A, Beijst C, Bruijnen R, et al. The superior predictive value of 166 Ho-scout compared with 99m Tc-macroaggregated albumin prior to 166 Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020;47:798\u2013806.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3656_CR7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s00330-017-4998-2","volume":"28","author":"AJAT Braat","year":"2018","unstructured":"Braat AJAT, Prince JF, van Rooij R, Bruijnen RCG, van den Bosch MAAJ, Lam MGEH. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018;28:920\u20138.","journal-title":"Eur Radiol"},{"key":"3656_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(12)70334-0","volume":"13","author":"MLJ Smits","year":"2012","unstructured":"Smits MLJ, Nijsen JFW, van den Bosch MAAJ, Lam MGEH, Vente MAD, Mali WPTM, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025\u201334.","journal-title":"Lancet Oncol"},{"key":"3656_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s002590050440","volume":"26","author":"JFW Nijsen","year":"1999","unstructured":"Nijsen JFW, Zonnenberg BA, Woittiez JRW, Rook DW, Swildens-Van Woudenberg IA, Van Rijk PP, et al. Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med. 1999;26:699\u2013704.","journal-title":"Eur J Nucl Med"},{"key":"3656_CR10","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1016\/S0142-9612(01)00055-2","volume":"22","author":"JFW Nijsen","year":"2001","unstructured":"Nijsen JFW, Van Steenbergen MJ, Kooijman H, Talsma H, Kroon-Batenburg LMJ, Van De Weert M, et al. Characterization of poly(l-lactic acid) microspheres loaded with holmium acetylacetonate. Biomaterials. 2001;22:3073\u201381.","journal-title":"Biomaterials"},{"key":"3656_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","volume":"31","author":"PA Yushkevich","year":"2006","unstructured":"Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31:1116\u201328.","journal-title":"Neuroimage"},{"key":"3656_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41747-020-00173-2","volume":"4","author":"J Hofmanninger","year":"2020","unstructured":"Hofmanninger J, Prayer F, Pan J, R\u00f6hrich S, Prosch H, Langs G. Automatic lung segmentation in routine imaging is primarily a data diversity problem, not a methodology problem. Eur Radiol Exp. 2020;4:1\u201313.","journal-title":"Eur Radiol Exp"},{"key":"3656_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ijrobp.2012.06.051","volume":"85","author":"N Yu","year":"2013","unstructured":"Yu N, Srinivas SM, Difilippo FP, Shrikanthan S, Levitin A, McLennan G, et al. Lung dose calculation with SPECT\/CT for 90Yittrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys. 2013;85:834\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3656_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1747-0803.2006.00037.x","volume":"1","author":"CP Cheng","year":"2006","unstructured":"Cheng CP, Taur AS, Lee GS, Goris ML, Feinstein JA. Relative lung perfusion distribution in normal lung scans: observations and clinical implications. Congnit Heart Dis. 2006;1:210\u20136.","journal-title":"Congnit Heart Dis"},{"key":"3656_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13550-014-0033-7","volume":"4","author":"YH Kao","year":"2014","unstructured":"Kao YH, Magsombol BM, Toh Y, Tay KH, Chow PKH, Goh ASW, et al. Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT\/CT for yttrium-90 radioembolization. EJNMMI Res. 2014;4:33.","journal-title":"EJNMMI Res"},{"issue":"2","key":"3656_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00270-020-02638-8","volume":"44","author":"M Elsayed","year":"2021","unstructured":"Elsayed M, Cheng B, Xing M, Sethi I, Brandon D, Schuster DM, Bercu Z, Galt J, Barron B, Kokabi N. Comparison of Tc-99m MAA planar versus SPECT\/CT imaging for lung shunt fraction evaluation prior to Y-90 radioembolization: are we overestimating lung shunt fraction? Cardiovasc Intervent Radiol. 2021;44(2):254\u201360.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"3656_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.jvir.2022.08.027","volume":"33","author":"N Kokabi","year":"2022","unstructured":"Kokabi N, Webster LA, Elsayed M, Switchenko JM, Chen B, Brandon D, Galt J, Sethi I, Cristescu M, Kappadath SC, Schuster DM. Accuracy and safety of scout dose resin yttrium-90 microspheres for radioembolization therapy treatment planning: a prospective single-arm clinical trial. J Vasc Interv Radiol. 2022;33(12):1578\u201387.","journal-title":"J Vasc Interv Radiol"},{"key":"3656_CR18","doi-asserted-by":"crossref","unstructured":"Kappadath SC, Lopez BP, Salem R, Lam MGEH. Reassessment of the lung dose limits for radioembolization. Nucl Med Commun 2021:1064\u201375.","DOI":"10.1097\/MNM.0000000000001439"},{"issue":"5","key":"3656_CR19","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1007\/s00259-020-05079-0","volume":"48","author":"C van Roekel","year":"2021","unstructured":"van Roekel C, van den Hoven AF, Bastiaannet R, Bruijnen RCG, Braat AJAT, de Keizer B, Lam MGEH, Smits MLJ. Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization-a prospective, within-patient randomized study. Eur J Nucl Med Mol Imaging. 2021;48(5):1658\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3656_CR20","doi-asserted-by":"crossref","unstructured":"Braat AJAT, Bruijnen RCG, van Rooij R, Braat MNGJA, Wessels FJ, van Leeuwaarde RS, van Treijen MJC, de Herder WW, Hofland J, Tesselaar MET, de Jong HWAM, Lam MGEH. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21(4):561\u201370.","DOI":"10.1016\/S1470-2045(20)30027-9"},{"key":"3656_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1148\/radiol.14131969","volume":"271","author":"RC Gaba","year":"2014","unstructured":"Gaba RC, Zivin SP, Dikopf MS, Parvinian A, Casadaban LC, Lu Y, et al. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting. Radiology. 2014;271:602\u201312.","journal-title":"Radiology"},{"key":"3656_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/annotation\/559e04cc-b09c-4b5c-9405-56837f6d5627","volume":"8","author":"MLJ Smits","year":"2013","unstructured":"Smits MLJ, van den Hoven AF, Rosenbaum CENM, Zonnenberg BA, Lam MGEH, Nijsen JFW, et al. Clinical and laboratory toxicity after intra-arterial radioembolization with 90Y-microspheres for unresectable liver metastases. PLoS ONE. 2013;8:1\u20139.","journal-title":"PLoS ONE"},{"key":"3656_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jvir.2022.07.032","volume":"34","author":"SR Miller","year":"2023","unstructured":"Miller SR, Jernigan SR, Abraham RJ, Buckner GD. Comparison of bolus versus dual-syringe administration systems on glass yttrium-90 microsphere deposition in an in vitro microvascular hepatic tumor model. J Vasc Interv Radiol. 2023;34:11\u201320.","journal-title":"J Vasc Interv Radiol"},{"key":"3656_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/cphy.c140049","volume":"6","author":"K Suresh","year":"2016","unstructured":"Suresh K, Shimoda LA. Lung circulation. Compr Physiol. 2016;6:897.","journal-title":"Compr Physiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03656-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-023-03656-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03656-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T16:02:27Z","timestamp":1712332947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-023-03656-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3656"],"URL":"https:\/\/doi.org\/10.1007\/s00270-023-03656-y","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"15 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marnix Lam is a consultant for Boston Scientific, Terumo\/Quirem Medical, and receives research support from Boston Scientific and AAA\/Novartis. Maarten Smits has served as a speaker for BTG and Terumo Medical. Arthur Braat is consultant for Boston Scientific\/BTG and Terumo\/Quirem Medical. All other authors declare to have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The Institutional Review Board granted approval for the Phase I and II Holmium Embolization Particles for Arterial Radiotherapy (HEPAR) studies, which are incorporated in this research. These studies are registered under Clinicaltrials.gov with the identifiers NCT01031784 and NCT01612325.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}